This site is intended for Healthcare professionals only.

Mylan teams up with Revance on biosimilar for Botox


Mylan teams up with Revance on biosimilar for Botox

NEW YORK: Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.

The deal includes an upfront payment of $25 million to Revance, Mylan said.

Revance’s own rival to Botox is not yet approved by the U.S. Food and Drug Administration. Revance reported positive Phase III data for its longer-lasting wrinkle treatment in December and said then that it planned to launch the drug in 2020, pending FDA approval.

(Reporting by Michael Erman; Editing by Susan Thomas)



Source: REUTERS
0 comment(s) on Mylan teams up with Revance on biosimilar for Botox

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted